世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
バイオシミラーに関する市場調査。製品価格の下落が市場成長を補うMarket Study on Biosimilars: Falling Product Prices to Supplement Market Growth バイオシミラー市場レポート範囲 世界のバイオシミラー市場に関するPersistence Market Researchの最新市場レポートは、機会や現在の市場シナリオを評価し、2022年から2032年の予測期間において市場に関わる対... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーバイオシミラー市場レポート範囲世界のバイオシミラー市場に関するPersistence Market Researchの最新市場レポートは、機会や現在の市場シナリオを評価し、2022年から2032年の予測期間において市場に関わる対応するセグメントについての洞察や最新情報を提供します。主要な市場力学の詳細な評価や、市場構造に関する包括的な情報を提供しています。2022-2032年の予測期間中に市場がどのように成長すると予想されるかについての詳細な洞察が含まれています。 本レポートの主な目的は、バイオシミラーに関連するグローバルビジネスの変革を支えている市場の機会に関する洞察を提供することです。常に変動する経済において、読者が市場の分析と評価をより良く理解し、この空間における有利な機会を発見できるように、全体的な予測のための複合年間成長率（CAGR）に加えて、推定（Y-oY）対前年成長率を提供するということは非常に重要であると考えています。 また、本レポートでは、市場規模の推定とそれに対応する絶対額での収益予測も行っています。また、市場の将来的な動向に基づいた実用的な洞察も提供しています。さらに、世界のバイオシミラー市場における新規参入企業や新興企業は、本調査で提示された情報を効果的なビジネス上の意思決定に活用することで、自社のビジネスだけでなく世界市場にも勢いを与えることができます。 本調査は、バイオシミラー市場のメーカー、サプライヤー、流通業者、投資家に関連するものです。すべての関係者、業界専門家、研究者、ジャーナリスト、ビジネス研究者は、本レポートに記載された情報とデータを活用することができます。 主な市場セグメント Persistence Market Research社の調査レポート「世界のバイオシミラー市場」は、製品タイプ、用途、流通チャネル、地域の4つのセグメントに分けて情報を提供しています。 製品タイプ 組換え糖鎖タンパク質 組換え非糖化タンパク質 応用分野 血液学 成長ホルモン欠乏症 腫瘍学 糖尿病 自己免疫疾患 疾患別 その他 販売チャネル 病院薬局 オンライン薬局 小売薬局 地域別 北アメリカ ラテンアメリカ 欧州 南アジア・太平洋 東アジア 中近東・アフリカ 本調査で回答した主な質問 予測期間中に最も高い市場シェアを占めるのはどの地域か？ 最も高い成長（CAGR）を遂げているのはどの地域か？ 世界のバイオシミラー産業に影響を及ぼしている要因は何か？ 市場に影響を与えている世界的なトレンドは何か？ 市場の様々な地域で機会を捉えるために、新興プレイヤーはどのような戦略を採用しなければなりませんか？ 世界のバイオシミラー市場の構造はどのようなものか？ 研究方法論 Persistence Market Research社は、お客様に偏りのない市場調査ソリューションを提供することに努めています。同社は、本レポートに含まれるデータの控除について、確固たる方法論に従っています。世界のバイオシミラー市場に関する広範な調査を実施し、市場の将来の成長要因に関する結論を得るために、独自の調査方法を利用しています。調査手法は、一次調査手法と二次調査手法の組み合わせで構成されており、本レポートの結論の正確性と信頼性を保証しています。 需要サイドのアプローチで対象製品の売上高を推定し、次に供給サイドのアプローチであらかじめ定義された期間における生成価値、主要トレンド、イベントに関する詳細な評価を行います。 この手法は、Persistence Market Researchが世界市場のセグメント化のために考慮する、北米、中南米、ヨーロッパ、南アジア・太平洋、東アジア、中東・アフリカの6地域以上の現地ソースからのインプットに基づく、標準の市場構造、手法、定義に基づいています。統計、特性、差異を地域レベルで収集し、同じレベルで集計し、世界レベルで統合して、世界市場の測定値を作成しています。 主な調査対象は以下の通りです。 プライマリーリサーチ セカンダリーリサーチ 貿易調査 ソーシャルメディアリサーチ 目次1. Executive Summary1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Technology Roadmap 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption / Usage Analysis 4.2. Product USPs / Features 4.3. Strategic Promotional Strategies 5. Global Biosimilars Market Demand Analysis 2017–2021 and Forecast, 2022–2032 5.1. Historical Market Volume (Tons) Analysis, 2017–2021 5.2. Current and Future Market Volume (Tons) Projections, 2022–2032 5.3. Y-o-Y Growth Trend Analysis 6. Global Biosimilars Market - Pricing Analysis 6.1. Regional Pricing Analysis By Product Type 6.2. Global Average Pricing Analysis Benchmark 7. Global Biosimilars Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032 7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Market Background 8.1. Macro-Economic Factors 8.1.1. Global GDP Growth Outlook 8.1.2. Global Industry Value Added Overview 8.1.3. Global Infrastructure Investment Overview 8.1.4. Global Construction Spending Analysis 8.1.5. Other Macro Economic Factors 8.2. Forecast Factors - Relevance & Impact 8.2.1. Top Companies Historical Growth 8.2.2. GDP Growth forecast 8.2.3. Construction Industry forecast 8.2.4. Distribution Channel Growth Outlook 8.2.5. Collaboration Activities 8.3. Value Chain 8.3.1. Raw Material Suppliers 8.3.2. List of Manufacturers 8.3.3. List of Distributors 8.4. COVID-19 Crisis – Impact Assessment 8.4.1. Current Statistics 8.4.2. Short-Mid-Long Term Outlook 8.4.3. Likely Rebound 8.5. Market Dynamics 8.5.1. Drivers 8.5.2. Restraints 8.5.3. Opportunity Analysis 8.5.4. Trends 9. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Product Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021 9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Product Type 2022–2032 9.3.1. Recombinant Glycosylated Proteins 9.3.2. Recombinant Non-Glycosylated Proteins 9.4. Market Attractiveness Analysis by Product Type 10. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021 10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032 10.3.1. Hematology 10.3.2. Growth Hormone Deficiency 10.3.3. Oncology 10.3.4. Diabetes Autoimmune 10.3.5. Disease 10.3.6. Others 10.4. Market Attractiveness Analysis By Application 11. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021 11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032 11.3.1. Hospital Pharmacies 11.3.2. Online Pharmacies 11.3.3. Retail Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021 12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia and Pacific 12.3.6. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032 13.4.1. By Country 13.4.1.1. U.S. 13.4.1.2. Canada 13.4.2. By Type 13.4.3. By Application 13.4.4. By Distribution Channel 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Type 13.5.3. By Application 13.5.4. By Distribution Channel 13.6. Market Trends 13.7. Key Market Participants - Intensity Mapping 13.8. Drivers and Restraints - Impact Analysis 14. Latin America Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. Brazil 14.4.1.2. Mexico 14.4.1.3. Rest of Latin America 14.4.2. By Type 14.4.3. By Application 14.4.4. By Distribution Channel 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Type 14.5.3. By Application 14.5.4. By Distribution Channel 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 15. Europe Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021 15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 15.4.1. By Country 15.4.1.1. Germany 15.4.1.2. Italy 15.4.1.3. France 15.4.1.4. U.K. 15.4.1.5. Spain 15.4.1.6. BENELUX 15.4.1.7. Russia 15.4.1.8. Rest of Europe 15.4.2. By Type 15.4.3. By Application 15.4.4. By Distribution Channel 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Type 15.5.3. By Application 15.5.4. By Distribution Channel 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16. South Asia and Pacific Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 16.4.1. By Country 16.4.1.1. India 16.4.1.2. ASEAN 16.4.1.3. Oceania 16.4.1.4. Rest of South Asia & Pacific 16.4.2. By Type 16.4.3. By Application 16.4.4. By Distribution Channel 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Type 16.5.3. By Application 16.5.4. By Distribution Channel 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17. East Asia Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 17.4.1. By Country 17.4.1.1. China 17.4.1.2. Japan 17.4.1.3. South Korea 17.4.2. By Type 17.4.3. By Application 17.4.4. By Distribution Channel 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Type 17.5.3. By Application 17.5.4. By Distribution Channel 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 18. Middle East and Africa Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 18.1. Introduction 18.2. Pricing Analysis 18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 18.4.1. By Country 18.4.1.1. GCC Countries 18.4.1.2. Turkey 18.4.1.3. Northern Africa 18.4.1.4. South Africa 18.4.1.5. Rest of Middle East and Africa 18.4.2. By Type 18.4.3. By Application 18.4.4. By Distribution Channel 18.5. Market Attractiveness Analysis 18.5.1. By Country 18.5.2. By Type 18.5.3. By Application 18.5.4. By Distribution Channel 18.6. Market Trends 18.7. Key Market Participants - Intensity Mapping 18.8. Drivers and Restraints - Impact Analysis 19. Emerging Countries Biosimilars Market Analysis 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Biosimilars Market Analysis 19.2.1. By Type 19.2.2. By Application 19.2.3. By Distribution Channel 19.3. Canada Biosimilars Market Analysis 19.3.1. By Type 19.3.2. By Application 19.3.3. By Distribution Channel 19.4. Mexico Biosimilars Market Analysis 19.4.1. By Type 19.4.2. By Application 19.4.3. By Distribution Channel 19.5. Brazil Biosimilars Market Analysis 19.5.1. By Type 19.5.2. By Application 19.5.3. By Distribution Channel 19.6. Germany Biosimilars Market Analysis 19.6.1. By Type 19.6.2. By Application 19.6.3. By Distribution Channel 19.7. Italy Biosimilars Market Analysis 19.7.1. By Type 19.7.2. By Application 19.7.3. By Distribution Channel 19.8. France Biosimilars Market Analysis 19.8.1. By Type 19.8.2. By Application 19.8.3. By Distribution Channel 19.9. U.K. Biosimilars Market Analysis 19.9.1. By Type 19.9.2. By Application 19.9.3. By Distribution Channel 19.10. Spain Biosimilars Market Analysis 19.10.1. By Type 19.10.2. By Application 19.10.3. By Distribution Channel 19.11. BENELUX Biosimilars Market Analysis 19.11.1. By Type 19.11.2. By Application 19.11.3. By Distribution Channel 19.12. Russia Biosimilars Market Analysis 19.12.1. By Type 19.12.2. By Application 19.12.3. By Distribution Channel 19.13. China Biosimilars Market Analysis 19.13.1. By Type 19.13.2. By Application 19.13.3. By Distribution Channel 19.14. Japan Biosimilars Market Analysis 19.14.1. By Type 19.14.2. By Application 19.14.3. By Distribution Channel 19.15. S. Korea Biosimilars Market Analysis 19.15.1. By Type 19.15.2. By Application 19.15.3. By Distribution Channel 19.16. India Biosimilars Market Analysis 19.16.1. By Type 19.16.2. By Application 19.16.3. By Distribution Channel 19.17. ASEAN Biosimilars Market Analysis 19.17.1. By Type 19.17.2. By Application 19.17.3. By Distribution Channel 19.18. Australia and New Zealand Biosimilars Market Analysis 19.18.1. By Type 19.18.2. By Application 19.18.3. By Distribution Channel 19.19. GCC Countries Biosimilars Market Analysis 19.19.1. By Type 19.19.2. By Application 19.19.3. By Distribution Channel 19.20. Turkey Biosimilars Market Analysis 19.20.1. By Type 19.20.2. By Application 19.20.3. By Distribution Channel 19.21. Northern Africa Biosimilars Market Analysis 19.21.1. By Type 19.21.2. By Application 19.21.3. By Distribution Channel 19.22. South Africa Biosimilars Market Analysis 19.22.1. By Type 19.22.2. By Application 19.22.3. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins) 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Pfizer Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Strategy Overview 21.3.2. Sandoz International GMBH 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Strategy Overview 21.3.3. Eli Lily & Company 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Strategy Overview 21.3.4. Hospira Inc. 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Strategy Overview 21.3.5. Amgen, Inc. 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Strategy Overview 21.3.6. Biocon Ltd. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Strategy Overview 21.3.7. Actavis, Inc. 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Strategy Overview 21.3.8. Cipla Ltd. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Profitability by Market Segments (Product/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Strategy Overview 21.3.9. Teva Pharmaceutical Industries, Ltd. 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Profitability by Market Segments (Product/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Strategy Overview 21.3.10. Dr. Reddy’s Laboratories Ltd. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Profitability by Market Segments (Product/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Strategy Overview 21.3.11. Celltrion, Inc. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Profitability by Market Segments (Product/Channel/Region) 21.3.11.4. Sales Footprint 21.3.11.5. Strategy Overview 21.3.12. Stada Arzeimittel Ag 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Profitability by Market Segments (Product/Channel/Region) 21.3.12.4. Sales Footprint 21.3.12.5. Strategy Overview 21.3.13. Mylan, Inc. 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Profitability by Market Segments (Product/Channel/Region) 21.3.13.4. Sales Footprint 21.3.13.5. Strategy Overview 21.3.14. Wockhardt Ltd. 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Profitability by Market Segments (Product/Channel/Region) 21.3.14.4. Sales Footprint 21.3.14.5. Strategy Overview 22. Assumptions and Acronyms Used 23. Research Methodology
SummaryBiosimilars Market: Report Scope Table of Contents1. Executive Summary1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Technology Roadmap 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption / Usage Analysis 4.2. Product USPs / Features 4.3. Strategic Promotional Strategies 5. Global Biosimilars Market Demand Analysis 2017–2021 and Forecast, 2022–2032 5.1. Historical Market Volume (Tons) Analysis, 2017–2021 5.2. Current and Future Market Volume (Tons) Projections, 2022–2032 5.3. Y-o-Y Growth Trend Analysis 6. Global Biosimilars Market - Pricing Analysis 6.1. Regional Pricing Analysis By Product Type 6.2. Global Average Pricing Analysis Benchmark 7. Global Biosimilars Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032 7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Market Background 8.1. Macro-Economic Factors 8.1.1. Global GDP Growth Outlook 8.1.2. Global Industry Value Added Overview 8.1.3. Global Infrastructure Investment Overview 8.1.4. Global Construction Spending Analysis 8.1.5. Other Macro Economic Factors 8.2. Forecast Factors - Relevance & Impact 8.2.1. Top Companies Historical Growth 8.2.2. GDP Growth forecast 8.2.3. Construction Industry forecast 8.2.4. Distribution Channel Growth Outlook 8.2.5. Collaboration Activities 8.3. Value Chain 8.3.1. Raw Material Suppliers 8.3.2. List of Manufacturers 8.3.3. List of Distributors 8.4. COVID-19 Crisis – Impact Assessment 8.4.1. Current Statistics 8.4.2. Short-Mid-Long Term Outlook 8.4.3. Likely Rebound 8.5. Market Dynamics 8.5.1. Drivers 8.5.2. Restraints 8.5.3. Opportunity Analysis 8.5.4. Trends 9. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Product Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021 9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Product Type 2022–2032 9.3.1. Recombinant Glycosylated Proteins 9.3.2. Recombinant Non-Glycosylated Proteins 9.4. Market Attractiveness Analysis by Product Type 10. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021 10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032 10.3.1. Hematology 10.3.2. Growth Hormone Deficiency 10.3.3. Oncology 10.3.4. Diabetes Autoimmune 10.3.5. Disease 10.3.6. Others 10.4. Market Attractiveness Analysis By Application 11. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021 11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032 11.3.1. Hospital Pharmacies 11.3.2. Online Pharmacies 11.3.3. Retail Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021 12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia and Pacific 12.3.6. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032 13.4.1. By Country 13.4.1.1. U.S. 13.4.1.2. Canada 13.4.2. By Type 13.4.3. By Application 13.4.4. By Distribution Channel 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Type 13.5.3. By Application 13.5.4. By Distribution Channel 13.6. Market Trends 13.7. Key Market Participants - Intensity Mapping 13.8. Drivers and Restraints - Impact Analysis 14. Latin America Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. Brazil 14.4.1.2. Mexico 14.4.1.3. Rest of Latin America 14.4.2. By Type 14.4.3. By Application 14.4.4. By Distribution Channel 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Type 14.5.3. By Application 14.5.4. By Distribution Channel 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 15. Europe Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021 15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 15.4.1. By Country 15.4.1.1. Germany 15.4.1.2. Italy 15.4.1.3. France 15.4.1.4. U.K. 15.4.1.5. Spain 15.4.1.6. BENELUX 15.4.1.7. Russia 15.4.1.8. Rest of Europe 15.4.2. By Type 15.4.3. By Application 15.4.4. By Distribution Channel 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Type 15.5.3. By Application 15.5.4. By Distribution Channel 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16. South Asia and Pacific Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 16.4.1. By Country 16.4.1.1. India 16.4.1.2. ASEAN 16.4.1.3. Oceania 16.4.1.4. Rest of South Asia & Pacific 16.4.2. By Type 16.4.3. By Application 16.4.4. By Distribution Channel 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Type 16.5.3. By Application 16.5.4. By Distribution Channel 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17. East Asia Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 17.4.1. By Country 17.4.1.1. China 17.4.1.2. Japan 17.4.1.3. South Korea 17.4.2. By Type 17.4.3. By Application 17.4.4. By Distribution Channel 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Type 17.5.3. By Application 17.5.4. By Distribution Channel 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 18. Middle East and Africa Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032 18.1. Introduction 18.2. Pricing Analysis 18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021 18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032 18.4.1. By Country 18.4.1.1. GCC Countries 18.4.1.2. Turkey 18.4.1.3. Northern Africa 18.4.1.4. South Africa 18.4.1.5. Rest of Middle East and Africa 18.4.2. By Type 18.4.3. By Application 18.4.4. By Distribution Channel 18.5. Market Attractiveness Analysis 18.5.1. By Country 18.5.2. By Type 18.5.3. By Application 18.5.4. By Distribution Channel 18.6. Market Trends 18.7. Key Market Participants - Intensity Mapping 18.8. Drivers and Restraints - Impact Analysis 19. Emerging Countries Biosimilars Market Analysis 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Biosimilars Market Analysis 19.2.1. By Type 19.2.2. By Application 19.2.3. By Distribution Channel 19.3. Canada Biosimilars Market Analysis 19.3.1. By Type 19.3.2. By Application 19.3.3. By Distribution Channel 19.4. Mexico Biosimilars Market Analysis 19.4.1. By Type 19.4.2. By Application 19.4.3. By Distribution Channel 19.5. Brazil Biosimilars Market Analysis 19.5.1. By Type 19.5.2. By Application 19.5.3. By Distribution Channel 19.6. Germany Biosimilars Market Analysis 19.6.1. By Type 19.6.2. By Application 19.6.3. By Distribution Channel 19.7. Italy Biosimilars Market Analysis 19.7.1. By Type 19.7.2. By Application 19.7.3. By Distribution Channel 19.8. France Biosimilars Market Analysis 19.8.1. By Type 19.8.2. By Application 19.8.3. By Distribution Channel 19.9. U.K. Biosimilars Market Analysis 19.9.1. By Type 19.9.2. By Application 19.9.3. By Distribution Channel 19.10. Spain Biosimilars Market Analysis 19.10.1. By Type 19.10.2. By Application 19.10.3. By Distribution Channel 19.11. BENELUX Biosimilars Market Analysis 19.11.1. By Type 19.11.2. By Application 19.11.3. By Distribution Channel 19.12. Russia Biosimilars Market Analysis 19.12.1. By Type 19.12.2. By Application 19.12.3. By Distribution Channel 19.13. China Biosimilars Market Analysis 19.13.1. By Type 19.13.2. By Application 19.13.3. By Distribution Channel 19.14. Japan Biosimilars Market Analysis 19.14.1. By Type 19.14.2. By Application 19.14.3. By Distribution Channel 19.15. S. Korea Biosimilars Market Analysis 19.15.1. By Type 19.15.2. By Application 19.15.3. By Distribution Channel 19.16. India Biosimilars Market Analysis 19.16.1. By Type 19.16.2. By Application 19.16.3. By Distribution Channel 19.17. ASEAN Biosimilars Market Analysis 19.17.1. By Type 19.17.2. By Application 19.17.3. By Distribution Channel 19.18. Australia and New Zealand Biosimilars Market Analysis 19.18.1. By Type 19.18.2. By Application 19.18.3. By Distribution Channel 19.19. GCC Countries Biosimilars Market Analysis 19.19.1. By Type 19.19.2. By Application 19.19.3. By Distribution Channel 19.20. Turkey Biosimilars Market Analysis 19.20.1. By Type 19.20.2. By Application 19.20.3. By Distribution Channel 19.21. Northern Africa Biosimilars Market Analysis 19.21.1. By Type 19.21.2. By Application 19.21.3. By Distribution Channel 19.22. South Africa Biosimilars Market Analysis 19.22.1. By Type 19.22.2. By Application 19.22.3. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins) 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Pfizer Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Strategy Overview 21.3.2. Sandoz International GMBH 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Strategy Overview 21.3.3. Eli Lily & Company 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Strategy Overview 21.3.4. Hospira Inc. 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Strategy Overview 21.3.5. Amgen, Inc. 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Strategy Overview 21.3.6. Biocon Ltd. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Strategy Overview 21.3.7. Actavis, Inc. 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Strategy Overview 21.3.8. Cipla Ltd. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Profitability by Market Segments (Product/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Strategy Overview 21.3.9. Teva Pharmaceutical Industries, Ltd. 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Profitability by Market Segments (Product/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Strategy Overview 21.3.10. Dr. Reddy’s Laboratories Ltd. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Profitability by Market Segments (Product/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Strategy Overview 21.3.11. Celltrion, Inc. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Profitability by Market Segments (Product/Channel/Region) 21.3.11.4. Sales Footprint 21.3.11.5. Strategy Overview 21.3.12. Stada Arzeimittel Ag 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Profitability by Market Segments (Product/Channel/Region) 21.3.12.4. Sales Footprint 21.3.12.5. Strategy Overview 21.3.13. Mylan, Inc. 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Profitability by Market Segments (Product/Channel/Region) 21.3.13.4. Sales Footprint 21.3.13.5. Strategy Overview 21.3.14. Wockhardt Ltd. 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Profitability by Market Segments (Product/Channel/Region) 21.3.14.4. Sales Footprint 21.3.14.5. Strategy Overview 22. Assumptions and Acronyms Used 23. Research Methodology
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（バイオ薬物）の最新刊レポート
Persistence Market Research社のバイオ薬物分野での最新刊レポート本レポートと同じKEY WORD（supplement）の最新刊レポートよくあるご質問Persistence Market Research社はどのような調査会社ですか?パーシスタンスマーケットリサーチ（Persistence Market Research/PMR）は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |
